TY - JOUR
T1 - Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice
AU - Gajra, Ajeet
AU - Zalenski, Abigail
AU - Sannareddy, Aishwarya
AU - Jeune-Smith, Yolaine
AU - Kapinos, Kandice
AU - Kansagra, Ankit
N1 - Funding Information:
Open access publication was funded by Cardinal Health. No external funding was used in the preparation of this article.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/6
Y1 - 2022/6
N2 - Chimeric antigen receptor T-cell (CAR-T) therapy is a revolutionary cancer treatment modality where a patient’s own T cells are collected and engineered ex vivo to express a chimeric antigen receptor (CAR). These reprogrammed CAR-T cells, when reinfused into the same patient, stimulate a T-cell mediated immune response against the antigen-expressing malignant cells leading to cell death. The initial results from pivotal clinical trials of CAR-T agents have been promising, leading to multiple approvals in various hematologic malignancies in the relapsed setting, including acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, follicular lymphoma, and, more recently, multiple myeloma. However, since the initial trials and US Food and Drug Administration approvals, there have been significant barriers to the widespread use of this therapy. The barriers to the use of CAR-T therapy include complex logistics, manufacturing limitations, toxicity concerns, and financial burden. This review discusses potential solutions to overcome these barriers in order to make this life-changing therapy widely accessible.
AB - Chimeric antigen receptor T-cell (CAR-T) therapy is a revolutionary cancer treatment modality where a patient’s own T cells are collected and engineered ex vivo to express a chimeric antigen receptor (CAR). These reprogrammed CAR-T cells, when reinfused into the same patient, stimulate a T-cell mediated immune response against the antigen-expressing malignant cells leading to cell death. The initial results from pivotal clinical trials of CAR-T agents have been promising, leading to multiple approvals in various hematologic malignancies in the relapsed setting, including acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, follicular lymphoma, and, more recently, multiple myeloma. However, since the initial trials and US Food and Drug Administration approvals, there have been significant barriers to the widespread use of this therapy. The barriers to the use of CAR-T therapy include complex logistics, manufacturing limitations, toxicity concerns, and financial burden. This review discusses potential solutions to overcome these barriers in order to make this life-changing therapy widely accessible.
UR - http://www.scopus.com/inward/record.url?scp=85131559226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131559226&partnerID=8YFLogxK
U2 - 10.1007/s40290-022-00428-w
DO - 10.1007/s40290-022-00428-w
M3 - Article
C2 - 35672571
AN - SCOPUS:85131559226
SN - 1178-2595
VL - 36
SP - 163
EP - 171
JO - Pharmaceutical Medicine
JF - Pharmaceutical Medicine
IS - 3
ER -